An announcement from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Limited has announced significant changes to its Board of Directors as part of a succession planning and renewal process. H Kevin McCann AO will retire as Non-Executive Director and Board Chairman, with Tiffany Olson set to succeed him. Additionally, Marie McDonald will join the Board as a Non-Executive Director and Chair of the People Committee. These changes aim to support Telix’s growth trajectory, global expansion, and recent Nasdaq dual-listing, enhancing the diversity and expertise within the Board.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan, focusing on oncology and rare diseases.
YTD Price Performance: 42.55%
Average Trading Volume: 4,631
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.48B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.